Zuellig Pharma and TopRidge Pharma Limited have signed a deal that will see Zuellig Pharma distribute Imdur, a mature medicine for the prevention of angina in patients with heart disease, in eight markets across the region.
Imdur was developed by global pharmaceutical company AstraZeneca who recently divested the global rights to the drug outside the US to TopRidge.
“We are proud to be entering into this relationship with TopRidge,” Zuellig Pharma Senior Vice President Commercial Solutions George Eassey said. “Imdur is a well-known product, with sales of $10 million in Southeast Asia in 2015. Our expertise in prolonging the life of mature brands means we are well placed to ensure Imdur’s presence in the region is extended to its full commercial potential.”
Yuandong Guo, Director of TopRidge, said: “We are pleased to be entering into this agreement with Zuellig Pharma. We think highly of its reputation and expertise. We believe working with a local partner through this commercial collaboration will maximize the value of the medicine in these markets”. “TopRidge was looking forward to the medicine’s strong performance in the eight markets”, he added.
